JP2002282208A - Dementia diagnosing apparatus - Google Patents

Abstract

PROBLEM TO BE SOLVED: To easily and correctly judge whether a subject has the Alzheimer's dementia or not by measuring the variation in the size of the pupil of the eye on the instillation side caused by a mydriatic agent. SOLUTION: The dementia diagnosing apparatus is for obtaining basic data for judging whether the dementia of a patient is the Alzheimer's dementia or the cerebrovascular dementia. The dementia diagnosing apparatus comprises a pupil imaging device 10, an operating device 2, and a display device 7. The pupil imaging device 10 is for taking an image of the pupil of the eye on the instillation side when a dilute mydriatic agent for diagnosing the Alzheimer's dementia is instilled into one eye with a constant illuminance. The operating device 2 is for measuring the size of the pupil of the eye based on the image taken by the pupil imaging device 10 within a prescribed period of time for measurement at prescribed intervals. The display device 7 is for displaying the variation of the measured size of the pupil of the eye as mydriasis data.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a dementia diagnostic apparatus for determining whether a dementia patient has Alzheimer-type dementia or cerebrovascular dementia.

[0002]

2. Description of the Related Art The number of patients with dementia is about 10 in Japan alone.
It is said that there are 10,000 people. This dementia can be subdivided into cortical dementia such as Alzheimer's dementia and Pick's disease, subcortical dementia such as Parkinson's disease and Huntington's disease, and cerebrovascular dementia. They are cerebrovascular dementia and Alzheimer's dementia, each accounting for about 50% or less.

At present, there are various types of therapeutic agents for cerebrovascular dementia, and their therapeutic effects have been recognized. As the therapeutic agents for Alzheimer-type dementia, acetylcholinesterase inhibitors have recently been developed. This treatment is not a fundamental treatment, but it can slow the progress of the disease,
If administered early, a sufficient therapeutic effect can be obtained. Therefore, it is effective to determine whether Alzheimer-type dementia or cerebrovascular dementia at an early stage of dementia, and to perform early treatment.

As a diagnosis of Alzheimer's dementia, Hasegawa scale (HDS) or MMSE (Mini
Mental State Examination) is known, and the score of the answer to a preset question is a predetermined cut-off point (20 points in the case of Hasegawa formula).
The following is a diagnosis of Alzheimer's dementia. However, in the case of early stage Alzheimer's dementia, a score higher than the cut-off point may be obtained based on the results of the interview, and at this time, if the diagnosis of Alzheimer's dementia is made, the efficacy of the acetylcholinesterase inhibitor is remarkable. Nevertheless, it is often diagnosed as normal.

[0005] For this reason, recently, a mydriatic diluent which causes a pupil dilation reaction when instilled in a patient with early stage Alzheimer's dementia has been developed, and this mydriatic diluent is applied to a subject. A method of diagnosing Alzheimer's dementia by measuring the diameter (area) of the pupil and determining the magnification after instillation has been published (US SCIENSE VOL.
266, 11 NOVEMBER 1994).

In the method, for example, a mydriatic diluent is instilled into the left eye, and the size of the pupil, for example, a change in the diameter of the pupil for 30 to 60 minutes is measured by a ruler, and the magnification is measured based on the change. It is determined whether or not Alzheimer-type dementia is present based on the magnitude of the magnification.

[0007]

However, the size of the pupil depends not only on the effect of the mydriatic, but also on the surrounding brightness and the like.
In general, the pupil image on the non-instillation side (right eye) is also taken at the same time, and its size is measured. There is a trouble that the user has to refer to the size of the pupil on the non-instilled side.

[0008] For this reason, it is difficult to quantitatively measure the change in the size of the pupil on the instillation side caused only by the mydriatic agent, and it is difficult to determine whether or not the patient has Alzheimer's dementia. There was a problem that they could be connected.
Further, since the diameter of the pupil is measured with a ruler, not only does a time shift occur when measuring the size of the left and right pupils, but also the measurement accuracy is low.

Further, when an early diagnosis of Alzheimer-type dementia is made, an anti-dementia drug such as an acetylcholinesterase inhibitor is administered to delay the progress, but the therapeutic drug is really effective for the patient. It has not been possible to determine quantitatively whether or not the dose has been determined, and it has been difficult to determine an appropriate dose.

[0010] Accordingly, the present invention is to easily and accurately determine whether or not Alzheimer's dementia is present by quantitatively measuring the change in the size of the pupil on the eye drop caused by only the mydriatic agent. The first task is to make it possible to perform the appropriate treatment by quantitatively grasping the effect of the Alzheimer's dementia therapeutic drug, confirming the therapeutic effect and making a definitive diagnosis. Doing so is the second task.

[0011]

Means for Solving the Problems In order to solve this problem, the invention of claim 1 provides basic data for determining whether a dementia patient has Alzheimer-type dementia or cerebrovascular dementia. A pupil imaging apparatus for obtaining a dementia diagnostic apparatus, wherein the pupil on the eye drop side when an Alzheimer's diagnostic mydriatic diluent is instilled into one eye with a fixed illuminance at a predetermined time interval within a predetermined measurement time. A display device for measuring the size of the pupil based on the image and displaying the measured change in the size of the pupil as mydriatic data.

According to the first aspect of the present invention, the pupil size is imaged with a constant illuminance that most affects the change in the pupil size. And the change in pupil size attributable solely to the mydriatic diluent can be measured.
Further, since the size of the pupil is measured from the captured image, a numerical value specifying the size, such as the diameter and area of the pupil, can be calculated extremely accurately.

Further, as in the second aspect of the present invention, if the size of the pupil on the eye drop side is normalized by the size of the pupil on the non-eye drop side measured at the same time, the size of the pupil due to factors other than the illuminance can be reduced. With the change removed, the change in pupil size due to only the mydriatic diluent can be measured more accurately. Therefore, even if the temporal change in the size of the pupil on the eye drop side is small, if the normalized pupil size increases with the passage of time, the pupil is enlarged by the mydriatic agent, so the Alzheimer's type It can be diagnosed as dementia. Also, even if the temporal change in the size of the pupil on the instillation side is large, if there is no significant change in the normalized data, the enlargement of the pupil on the instillation side is caused by other factors,
Since the pupil is not enlarged by the mydriatic agent, it can be diagnosed as not Alzheimer's dementia.

In this case, if the size of the pupil is represented by a ratio to the size of the pupil before or immediately after the instillation, the ratio can be calculated by the ratio to the size of the pupil before or immediately after the instillation.
Since the size of the pupil in the initial state becomes 100% and the size of the pupil measured after instillation directly represents the magnification, the comparison becomes extremely easy.

The pupil image is, for example, 60 images at 5 minute intervals.
Although images are taken for one minute, if it is attempted to image five patients every minute in order to improve examination efficiency, it may be unclear which pupil image is the pupil image of which patient. Therefore, when the pupil image is captured by the pupil imaging device, the iris pattern is stored, and each time the pupil image is input, the iris pattern is stored in advance. If iris pattern identification means is provided for comparing with the pupil image, the pupil image of the same patient can be found immediately even if the patient name is not recorded.

Furthermore, if the pupil imaging device and the arithmetic processing device are provided with a transmitter and a receiver for wirelessly transmitting and receiving the captured pupil image, there is no connection code for connecting the two, so that there is no trouble in wiring. Not only does it make connection mistakes.

According to the third and fourth aspects of the present invention, there is provided a questionnaire result input device for inputting the result based on an answer to each question of a preset dementia diagnosis questionnaire test, and a score corresponding to the result of each question. The present invention is characterized in that an inquiry test execution means having an arithmetic device for summing is provided.

According to the third and fourth aspects of the present invention, first, the Hasegawa scale (HD
When an answer to each question of S) or MMSE is input, a total score for the answer is calculated. If this score is lower than a predetermined cutoff point (20 points on Hasegawa scale), it is diagnosed as Alzheimer's dementia. Will be done. However, if the score is higher than the cut-off point, the possibility of early Alzheimer's dementia or cerebrovascular dementia remains, so a mydriatic test was performed, and as a result, the pupil dilated. For example, it can be diagnosed as Alzheimer's dementia even if it is higher than the cutoff point, and if the pupil does not expand, it can be diagnosed that suspicion of cerebrovascular dementia is extremely high.

[0019] The invention of claim 8 is a dementia diagnostic apparatus for monitoring the therapeutic effect of a drug for treating Alzheimer's dementia, wherein the pupil on the eye drop side when one of the diluents for the diagnosis of Alzheimer's diagnostic is applied to one eye. The size of the pupil is measured based on the image of the pupil imaging device that images the pupil at a predetermined time interval within a predetermined measurement time at a constant illuminance, and a change in the measured pupil size is stored as mydriatic data. Mydriatic test execution means, and before and after the administration of the therapeutic agent for Alzheimer's dementia, each mydriatic data measured by the mydriatic test execution means by instilling a mydriatic diluent into the pupils on the same side on the left and right sides. And a display device for displaying.

According to the ninth aspect of the present invention, before and after administration of the therapeutic agent for dementia of Alzheimer's type, each of the mydriatic data measured by instilling a mydriatic diluent into the pupils on the same side on the left and right sides is displayed. Therefore, it can be determined that the therapeutic agent is effective if the magnification is small before and after administration.

[0021]

Embodiments of the present invention will be specifically described below with reference to the drawings. 1 is an overall configuration diagram showing an example of a dementia diagnosis apparatus according to the present invention, FIG. 2 is a flowchart showing a processing procedure of the apparatus of the present invention, FIG. 3 is a chart showing the contents of a question on a Hasegawa scale, and FIGS. Is a graph showing the measurement results.

The dementia diagnostic apparatus 1 of this embodiment obtains basic data for determining whether a dementia patient has Alzheimer's dementia or cerebrovascular dementia, and treats a drug for treating Alzheimer's dementia. This is to confirm the effect.

The dementia diagnosis apparatus 1 is a computer main unit 4 having an arithmetic unit 2 for performing data processing according to a predetermined program and a storage unit 3 for storing data and programs.
Input device 6 such as a keyboard 6a and a mouse 6b, and a display device (display device) for displaying the operation result of the arithmetic device 2 and the input characters of the input device 6, etc.
7 and a printer (display device) 8 for printing an image displayed on the display device 7 are connected.

A receiver 9 for receiving an image signal transmitted wirelessly is connected to the input / output port 5,
The pupil image transmitted from the transmitter 11 provided in the pupil imaging device 10 that simultaneously captures the left and right pupils is received and input to the arithmetic unit 2.

The pupil image pickup device 10 is provided, for example, in a goggle-type mask that can be worn on the face or in a binocular lens barrel configured to look through both eyes, facing the left and right pupil positions.
Two imaging cameras 12L and 12 for individually imaging each pupil
R, LED illumination 13 for illuminance adjustment, illuminance sensor 14,
An imaging infrared LED illumination 15 is provided. The illuminance adjustment LED illumination 13 and the illuminance sensor 14 are connected to the illuminance controller 16 to maintain a constant illuminance condition at the time of pupil photographing so that a measurement error does not occur.
It is sufficient that at least one LED illumination 13 for illuminance adjustment is disposed so as to face the upper and lower positions or the left and right positions of the eyeball. The direction in which the light is reflected in the imaging device 10 and then indirectly radiated so as to be incident on the eyeball may be used.
The LED used for the illuminance adjustment LED illumination 13 is preferably a visible light color, but may be an infrared light, and its emission color is not limited.

FIG. 2 shows a data processing procedure by the dementia diagnosis apparatus 1. When the diagnostic apparatus 1 is started up, an inquiry test execution means (steps STP1 to 3) is started. First, in step STP1, a question content and an answer of a preset diagnosis test for dementia diagnosis such as Hasegawa scale (HDS) are answered. Since the entry field is displayed, the doctor sequentially asks questions based on the entry fields, and sequentially inputs the answers using the keyboard 6a and the mouse 6b.

When all the questions have been completed and the answer has been entered and the confirmation key (for example, the Eenter key) has been hit, the process proceeds to step STP2. A total score corresponding to the answer is calculated. Next, the process proceeds to step STP3, where each answer, total score, and a code (name or ID) for specifying the patient are stored in a folder Fn created in advance in a predetermined storage area of the storage device 3.
Code) is recorded.

In the Hasegawa scale, 20 points are the cut-off point, and if the score is 20 points or less, it is diagnosed as Alzheimer's dementia. However, if the total score is 21 to 26 points, dementia is suspected. The above is determined to be normal. Therefore, in step STP4, the total score is 20 points or less,
It is determined whether the score is 21 to 26 points or 27 points or more. If the score is 20 points or less and 27 points or more, step STP
In step 5, whether the Alzheimer-type dementia is normal or not is displayed, and the process ends. If the score is 21 to 26, the process proceeds to the mydriatic test execution means in steps STP6 to STP15, and it is determined whether the disease is an early stage of Alzheimer's dementia or cerebrovascular dementia.

Mydriatic test execution means (steps STP6-1)
When the process proceeds to 5), the left and right pupils are simultaneously imaged at predetermined time intervals before or immediately after instillation of the mydriatic diluent for Alzheimer's diagnosis into one eye, and a pupil image is captured. First, in step STP6, the pupil imaging device 10 simultaneously captures the left and right pupils to capture a pupil image. At the same time, based on the images, the iris pattern is recognized, and the process proceeds to step STP7.

In step STP7, each folder Fn
Is compared with the iris pattern stored in the iris pattern, and if they match, the process proceeds to step STP8 to store the image data of the pupil image in the folder Fn in which the matched iris pattern is recorded. Goes to step STP9 and stores it in the previously created folder Fn for the patient. Thereby, a patient who has already taken a pupil image is automatically stored in the folder Fn of the same patient without assigning a patient name, so that the trouble of managing the pupil image is significantly reduced. You.

Next, in step STP10, step STP
If it is determined that the processes 6 to 9 have been repeated a predetermined number of times at a predetermined time interval within a predetermined measurement time (for example, 13 times when pupil changes for 60 minutes are imaged every 5 minutes), the process proceeds to step STP11. Transition. In addition, in the case of imaging every 5 minutes, even if the pupil of another person is imaged during that time, the pupil image is automatically stored in the folder Fn of each patient. I don't know if it's there.

In step STP11, the size of the pupil at each measurement time is calculated. Specifically, when an area is used as the size of the pupil, for example, the ratio is calculated as a ratio (mydriatic ratio) when the area of the left and right pupils before or immediately after the instillation is set to 100%.

Then, in step STP12, the mydriatic rate on the eye drop side of the diluent for dizziness of Alzheimer's diagnosis is normalized by dividing the mydriatic rate on the non-ophthalmic side measured simultaneously, and the change is used as mydriatic data. Remember.

In step STP13, the change of the left and right mydriasis ratios and mydriasis data are displayed on the display device 7, and their graph images are stored in the same folder Fn, and output by the printer 8 as necessary.

In this example, generally, when the pupil area exceeds 127% (113% in diameter) by the mydriatic test, the possibility of Alzheimer's dementia is extremely high, and therefore, as shown in FIGS. 4 and 5. When the mydriatic data is displayed as a graph, it is desirable to attach a determination reference line M of 127% of the pupil area.

Next, in step STP14, the average value is calculated based on the mydriatic data, and in step STP15, the average value is calculated.
A graph plotting points where the scores of the dementia diagnosis interview test as shown in FIG. 7 are set as the X coordinate and the average value of the mydriatic data is set as the Y coordinate is displayed on the display device 7, and the graph image is stored in the folder Fn. This is output by the printer 8 if necessary, and the process is terminated.

In this case, the graph shows orthogonal cutoff points CP and A representing the cutoff point of the dementia diagnosis interview test and the size of the pupil as a criterion for determining Alzheimer's dementia.
If H is displayed, the region R ₁ on the left side of the reference line CP is displayed.
Is cerebrovascular dementia when plotted in Alzheimer-type dementia, below the and reference line AH at the right side of the reference line CP region R ₃ when plotted and the reference line AH over the regions R ₂ Is determined.

When the points of the Hasegawa scale (HDS) are used for the X coordinate, the reference line CP is 20 points, when the average value of the mydriatic data is used as the Y coordinate, the reference line AH is 125 to 135 in pupil area. % (112-116% of pupil diameter),
Optimally, 129-130% in pupil area (1 in pupil diameter)
14%).

The mydriatic data is obtained by dividing the mydriatic rate on the instilled side by the mydriatic rate on the non-instilled side, based on the mydriatic rate when the area of the pupil before or immediately after instillation is 100%. Although the normalized value is used, the present invention is not limited to this, and a numerical value that specifies the size of the pupil, such as the mydriatic rate on the eye drop side, can be selected.

In this case, the Y axis represents the pupil size such as the normalized maximum pupil ratio, the average value of the pupil ratio on the eye drop side, or the maximum value of the pupil ratio on the eye drop side. Any numerical value representing the change can be used. When the normalized maximum value of the mydriatic ratio is used as the Y coordinate, the reference line AH has a pupil area of 155 to 165% (a pupil diameter of 125 to 128%).
%), Optimally between 159 and 160% in pupil area (126% in pupil diameter). When the average value of the mydriatic rate on the eye drop side is used as the Y coordinate, the reference line AH is 115 to 120% in pupil area (107 to 109% in pupil diameter), and optimally 117 to 118 in pupil area. % (10 in pupil diameter)
8%). Further, when the maximum value of the mydriatic ratio on the eye drop side is used as the Y coordinate, the reference line AH is 145 in pupil area.
１５155% (120-125% pupil diameter), optimally 150% pupil area (122% pupil diameter).

When the mydriatic data and the average and maximum values of the mydriatic rate are used as the Y coordinate in this manner, a measurement time of at least 20 minutes or more is required, and a graph based on the data obtained when the measurement is terminated in less than 20 minutes is required. Could not accurately distinguish between Alzheimer's dementia and cerebral vascular dementia, but when measured at least 40 minutes, 40 minutes, 50 minutes, and 60 minutes, the measurement was longer. Even so, there was no change in the results.

The use of the dementia diagnostic apparatus 1 can monitor the therapeutic effect of a drug for treating Alzheimer's dementia. In this case, the physician said that before the therapeutic drug for Alzheimer's dementia was administered, the mydriasis data was stored by performing the processing of the above-mentioned steps STP6 to STP13, and after the administration of the therapeutic drug had started, the physician should confirm the efficacy. When admitted,
Again, the processing of steps STP 6 to STP 15 is performed to store the mydriatic data, and both are displayed on the same graph as shown in FIG. 7 or on separate graphs, and these are compared. Do.

In this case, when the pupil image is taken after the start of administration of the therapeutic agent, for example, one month later, since the pupil image has already been taken by the iris pattern, the iris pattern of the image is collated. Automatically folder Fn of the same patient
Therefore, there is no need to add a patient name to the image data and manage the pupil image.

4 to 7 are graphs obtained by the dementia diagnosis apparatus 1. FIG. 4 and FIG. 5 show that the total score of the Hasegawa scale was 21 to 26 points, the mydriatic diluent was instilled into the left eye, the saline was instilled into the right eye, and 5 minutes from immediately after the instillation.
The results obtained when a mydriatic test for imaging the pupil for a total of thirteen times for 60 minutes every minute are shown. The one-dot chain line, the two-dot chain line, and the solid line indicate the mydriatic rate on the instillation side, the mydriatic rate on the non-instillation side, and The normalized mydriatic rate (mydriatic data) is shown.

According to the results shown in FIG. 4, the mydriasis data reaches 130% after 25 minutes have passed, and since the mydriasis data does not decrease thereafter and tends to expand, if such data is obtained, It can be diagnosed that the suspicion of Alzheimer's dementia is high.

According to the results shown in FIG. 5, since the mydriasis data does not reach 127% and stays at around 100%, if such data is obtained, the Alzheimer-type dementia Suspicion of cerebrovascular dementia can be diagnosed as extremely high.

FIG. 6 shows the pupil data of many patients measured on the basis of pupil images taken every 5 minutes within the measurement time of 40 minutes, using the Hasegawa scale (HDS) score as the X coordinate. 5 shows a graph in which points where the average value is set as a Y coordinate are plotted. A cut-off point of the dementia diagnosis interview test and a reference line CP, which represents the size of the pupil, which is a criterion for determining Alzheimer's type dementia, are bordered by AH. is plotted from the left region R ₁ or baseline AH over the regions R _2, patients displayed cerebrovascular dementia circular, from and reference line AH at the right side of the reference line CP under the region R ₃ Plotted. Thus, the region R ₁ or R ₂
When plotted can and be diagnosed with Alzheimer's disease, when plotted in the region R ₃ it can be seen that diagnosed with cerebrovascular dementia to.

FIG. 7 is a graph showing the mydriasis data of an Alzheimer-type dementia patient prescribed an anti-dementia drug such as an acetylcholinesterase inhibitor before administration and one month after administration. It is a thing. According to this graph, in comparison to mydriasis data D ₁ of the pre-dose illustrated by broken lines, since a small pupillary mydriasis data D ₂ when 1 month has passed after administration illustrated by the solid line, the therapeutic agent is You can see that it works. By describing on the same graph in this way, comparison becomes easy, and it is possible to objectively know how effective the therapeutic agent is and its therapeutic effect.

In the description of the embodiment, the pupil imaging device 1
Although the case where both the left and right eyes are simultaneously imaged at 0 and the pupil size is calculated based on the respective pupil images has been described, the present invention is not limited to this, and only the pupil on the eye drop side is imaged. The size of the pupil may be calculated. The concentration of the mydriatic agent is 0.01% and 0.0075.
%, 0.0050%, 0.0025% tropicamide can be used, and pilocarbine hydrochloride may be used instead. Further, when the pupil is imaged by the imaging device 10, the illuminance near the eyeball is 110 lux, 13 lux.
It is desirable to maintain it at about 0 lux and 150 lux.

[0050]

As described above, according to the present invention, the size of the pupil on the instillation side is normalized by the size of the pupil on the non-instillation side which is crowded simultaneously, so that only the mydriatic agent is used. Anyone can quantitatively measure the resulting change in the size of the pupil on the eye drop side, and has an extremely excellent effect that it is possible to easily and accurately determine whether or not Alzheimer's dementia is present. . In addition, by performing a mydriatic test before and after administration of a drug for treating Alzheimer's dementia and comparing the pupil areas, it can be easily determined whether or not the therapeutic effect of the therapeutic agent has appeared, and optimal administration There is also an effect that reference data for determining the amount can be used.

[Brief description of the drawings]

FIG. 1 is an overall configuration diagram showing an example of a dementia diagnosis apparatus according to the present invention.

FIG. 2 is a flowchart showing a processing procedure of the apparatus of the present invention.

FIG. 3 is a chart showing the contents of a question on a Hasegawa scale.

FIG. 4 is a graph showing measurement results.

FIG. 5 is a graph showing measurement results.

FIG. 6 is a graph showing measurement results.

FIG. 7 is a graph showing measurement results.

[Explanation of symbols]

 DESCRIPTION OF SYMBOLS 1 ... Dementia diagnosing device 2 ... Operation device 3 ... Storage device 4 ... Computer body 5 ... Input / output port 6 ... Input device 7 ... Display device (display device) 8 ... Printer (display device) 9 Receiver 10 Pupil imaging device 11 Transmitters 12R, 12L Pupil image imaging device

Claims (10)

[Claims] 1. A dementia diagnostic apparatus for obtaining basic data for determining whether a dementia patient has Alzheimer-type dementia or cerebrovascular dementia, comprising: An arithmetic unit (10) that measures the size of the pupil at a predetermined time interval within a predetermined measurement time based on an image of the pupil imaging device (10) that captures the pupil on the eye drop side at a constant illuminance when the liquid is instilled. 2)
And a display device (7) for displaying the measured change in pupil size as mydriatic data. 2. A dementia diagnostic apparatus for obtaining basic data for determining whether a dementia patient has Alzheimer-type dementia or cerebrovascular dementia, wherein one of the eyes has a mydriatic dilution for Alzheimer diagnosis. The size of the pupil is measured at predetermined time intervals within a predetermined measurement time based on an image of a pupil imaging device (10) for imaging the pupil on the eye drop side at a constant illuminance when the liquid is instilled. An arithmetic unit (2) for normalizing the normalized pupil size with the pupil size of the non-instilled eye taken at the same time, and a display device for displaying a change in the normalized pupil size as mydriatic data ( 7) A diagnostic device for dementia, comprising: 3. A dementia diagnosis apparatus for obtaining basic data for determining whether a dementia patient has Alzheimer's type dementia or cerebrovascular dementia, comprising: a pre-set diagnostic test for dementia diagnosis. A questionnaire test execution means (STP1 to STP1) including a questionnaire result input device (6) for inputting the result based on the answer to each question and a computing device (2) for summing up the scores corresponding to the results of each question.
3) and determining the size of the pupil based on the image of the pupil imaging device (10) that captures the pupil on the eye drop side at a constant illuminance when the diluent for Alzheimer's diagnosis is instilled into one eye. A mydriatic test execution means (STP6 to 15) for measuring at a predetermined time interval within the measurement time of the pupil and displaying the measured change in the size of the pupil as mydriatic data. apparatus. 4. A dementia diagnosis apparatus for obtaining basic data for determining whether a dementia patient has Alzheimer's type dementia or cerebrovascular dementia, comprising: a pre-set diagnosis test for dementia diagnosis; A questionnaire result input device (6) for inputting the result of each question, and a questionnaire test execution means (STP1 to 3) including an arithmetic device (2) for summing the scores corresponding to the results of each question; The size of the pupil is determined within a predetermined measurement time on the basis of an image of a pupil imaging device (10) that captures the pupil on the eye drop side at a constant illuminance when the diluent for Alzheimer's diagnosis is applied to the eye. Mydriasis that measures at the time interval and normalizes the measured pupil size with the pupil size on the non-instillation side imaged at the same time, and displays the normalized change in pupil size as mydriatic data Test execution means (STP
6 to 15), wherein a dementia diagnostic apparatus is provided. 5. The medical examination test execution means (STP1-3)
5. The control device according to claim 3, further comprising a control device that executes a process by a mydriatic test execution means when the total score calculated in step S is near or above a preset cutoff point. Dementia diagnosis device. 6. The apparatus for diagnosing dementia according to claim 3, wherein the dementia diagnosis interview test is Hasegawa scale or MMSE. 7. A reference line indicating a cut-off point of the dementia diagnosis interview test, where the point of the dementia diagnosis interview test and the point where the average or maximum value of the size of the pupil on the instillation side is the XY coordinate. 5. The apparatus for diagnosing dementia according to claim 3, further comprising a display device (7) for plotting on a graph on which a reference line indicating the size of a pupil as a criterion for Alzheimer's dementia is displayed. 8. A dementia diagnostic apparatus for monitoring the therapeutic effect of a drug for treating Alzheimer's type dementia, wherein the pupil on the eye drop side with a constant illuminance when one eye is instilled with an Alzheimer's diagnostic mydriatic diluent. Based on the image of the pupil imaging device (10) to be imaged, the size of the pupil is measured at predetermined time intervals within a predetermined measurement time, and the measured change in pupil size is stored as mydriatic data. Mydriatic test executing means (STP6 to 15); and mydriatic test executing means (STP6 to 15) by applying a mydriatic diluent to the pupils on the same side on the left and right sides before and after administration of the therapeutic drug for Alzheimer's dementia. A display device (7) for displaying each mydriasis data measured according to (1). 9. A dementia diagnostic apparatus for monitoring the therapeutic effect of a drug for treating Alzheimer's dementia, wherein the pupil on the eye drop side with a constant illuminance when one eye is instilled with an Alzheimer's diagnostic mydriatic diluent. Based on the image of the pupil imaging device (10) to be imaged, the size of the pupil is measured at predetermined time intervals within a predetermined measurement time, and the measured pupil size is measured on the non-instillation side at the same time. Mydriatic pupil test execution means (STP) that normalizes the pupil size and stores the normalized change in pupil size as mydriatic data.
6 to 15), and before and after administration of the therapeutic agent for Alzheimer's dementia, each of the mydriatic data measured by the mydriatic test executing means by instilling a mydriatic diluent into the pupils on the same side on the left and right sides. A dementia diagnosis device comprising a display device (7). An iris pattern is stored when a pupil image is captured by the pupil imaging device, and the iris pattern is stored every time a pupil image is input. An apparatus for diagnosing dementia according to any one of claims 1 to 9, further comprising an iris pattern identification unit (STP7) for collating with the iris pattern.